Hematopoiesis News Volume 15.16 | Apr 30 2024

    By
    Noshin Noorjahan
    -
    0
    14







    2024-04-30 | HN 15.16


    Hematopoiesis News by STEMCELL Technologies
    Vol. 15.16 – 30 April, 2024
    TOP STORY

    Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

    The authors conducted an open-label, single-group, Phase III study of exagamglogene autotemcel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β0/β0, β0/β0-like, or non–β0/β0-like genotype.
    [New England Journal Of Medicine]

    Abstract
    Access scientific and product support from STEMCELL Technologies
    PUBLICATIONSRanked by the impact factor of the journal

    Putting the STING Back into BH3-Mimetic Drugs for TP53-Mutant Blood Cancers

    Investigators reported that p53 was activated following BH3-mimetic induced mitochondrial outer membrane permeabilization, leading to BH3-only protein induction and thereby potentiating the pro-apoptotic signal.
    [Cancer Cell]

    Full ArticleGraphical Abstract

    GPATCH8 Modulates Mutant SF3B1 Mis-Splicing and Pathogenicity in Hematologic Malignancies

    The authors utilized synthetic introns uniquely responsive to mutant SF3B1 to identify trans factors required for aberrant mutant SF3B1 splicing activity.
    [Molecular Cell]

    Full ArticleGraphical Abstract

    The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells

    Scientists designed MP0533, a multispecific CD3-engaging designed ankyrin repeat protein that could simultaneously bind to three antigens on AML cells, CD33, CD123, and CD70, aiming to enable avidity-driven T cell–mediated killing of AML cells co-expressing at least two of the antigens.
    [Cancer Immunology Research]

    Abstract

    Pyrimidine Depletion Enhances Targeted and Immune Therapy Combinations in Acute Myeloid Leukemia

    Researchers introduced HOSU-53, a dihydroorotate dehydrogenase inhibitor with significant monotherapy activity, which was further enhanced when combined with other standard-of-care therapeutics.
    [JCI Insight]

    Full Article

    Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

    Scientists elucidated the molecular architecture and kinetics preceding AML relapse by utilizing error-corrected next-generation sequencing in 74 AML patients relapsing after alloHCT evaluating 140 samples from peripheral blood collected 0.6 to 14 months before relapse.
    [Blood]

    Abstract

    Clonal Hematopoiesis–Derived Therapy-Related Myeloid Neoplasms after Autologous Hematopoietic Stem Cell Transplant for Lymphoid and Non-Lymphoid Disorders

    Investigators studied a cohort of 1507 patients undergoing autologous hematopoietic stem cell transplantation (aHSCT) and a cohort of 263 patients who developed therapy-related myeloid neoplasms (tMN) without aHSCT to determine clinico-molecular features unique to post-aHSCT tMN.
    [Leukemia]

    Full Article

    Subsequent Malignant Neoplasms after Primary Hematological Malignancy in Adult Patients

    The authors identified 45,533 patients aged ≥20 years and diagnosed with primary hematological malignancy in Finland from 1992 to 2019 from the Finnish Cancer Registry and estimated standardized incidence ratios and excess absolute risks per 1000 person-years for subsequent malignant neoplasms.
    [International Journal of Cancer]

    Full ArticleGraphical Abstract

    Mis-Expression of GATA6 Re-programs Cell Fate during Early Hematopoiesis

    In Max41 transgenic mice, nearly all B cells diverted into the granulocyte lineage. Investigators showed that these mice had an excess of myeloid progenitors, but their common lymphoid progenitor compartment was ablated, and they had few plasmacytoid dendritic cells.
    [Cell Reports]

    Full ArticleGraphical Abstract
    See how small molecules affect key signaling pathways in cancer research. Download your free wallchart now.
    REVIEWS

    Not Just for Lymphoid Cells: The Role of the Noncanonical NF-κB Signaling Pathway in Early and Late Myelopoiesis with a Focus on Hypereosinophilic Disorders

    Scientists discuss the molecular machinery within the noncanonical NF-κB pathway, crosstalk with the canonical NF-κB pathway, murine models of noncanonical signaling, as well as how aberrations in this pathway manifest in leukemic or hyperinflammatory disease with a focus on Hypereosinophilic syndrome.
    [Journal of Leukocyte Biology]

    Abstract
    INDUSTRY AND POLICY NEWS

    $2.7 Million Grant to Explore Hypoxia’s Impact on Blood Stem Cells

    A new four-year, $2.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases will support the project, “Hypoxia’s role in regulating stressed hematopoietic stem cells,” led by Indiana University School of Medicine scientists.
    [Indiana University School of Medicine (EurekAlert)]

    Press Release
    FEATURED EVENT

    ISCT 2024

    May 29 – June 1, 2024
    Vancouver, British Columbia, Canada

    > See All Events

    JOB OPPORTUNITIES

    Assistant Research Scientist – Megakaryocyte-Bone Cell-Hematopoietic Cell Interactions

    Indiana University – Indiana, Pennsylvania, United States

    Research Assistant – Bioinformatics, Computational Biology, Systems Immunology

    University of Duisburg-Essen – Duisburg-Essen, Germany

    Postdoctoral Research Associate – Biology of B Cells and Pathogenesis of Lymphomas and Leukemias

    University of Duisburg-Essen – Duisburg-Essen, Germany

    Postdoctoral Research Associate – Tissue Injury

    University of Illinois at Chicago – Chicago, Illinois, United States

    Staff Scientist – Myeloid Cell Regulation, Cancer, and Immunotherapy

    Wistar Institute – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2